HomeCompareVCRA vs JNJ

VCRA vs JNJ: Dividend Comparison 2026

VCRA yields 2.53% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $6.8K in total portfolio value· pulled ahead in Year 8
10 years
VCRA
VCRA
● Live price
2.53%
Share price
$79.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.5K
Annual income
$297.54
Full VCRA calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — VCRA vs JNJ

📍 JNJ pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVCRAJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VCRA + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VCRA pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VCRA
Annual income on $10K today (after 15% tax)
$214.84/yr
After 10yr DRIP, annual income (after tax)
$252.91/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,733.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VCRA + JNJ for your $10,000?

VCRA: 50%JNJ: 50%
100% JNJ50/50100% VCRA
Portfolio after 10yr
$26.9K
Annual income
$2,493.47/yr
Blended yield
9.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VCRA
Analyst Ratings
13
Buy
13
Hold
Consensus: Buy
Price Target
$46.00
-41.9% upside vs current
Range: $46.00 — $46.00
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VCRA buys
0
JNJ buys
0
No recent congressional trades found for VCRA or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVCRAJNJ
Forward yield2.53%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$23.5K$30.3K
Annual income after 10y$297.54$4,689.40
Total dividends collected$2.8K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$46.00$228.73

Year-by-year: VCRA vs JNJ ($10,000, DRIP)

YearVCRA PortfolioVCRA Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,953$252.75$10,592$272.30+$361.00VCRA
2$11,978$258.72$11,289$357.73+$689.00VCRA
3$13,081$264.43$12,123$472.89+$958.00VCRA
4$14,267$269.89$13,141$629.86+$1.1KVCRA
5$15,540$275.09$14,408$846.81+$1.1KVCRA
6$16,908$280.05$16,021$1,151.60+$887.00VCRA
7$18,377$284.76$18,122$1,588.22+$255.00VCRA
8← crossover$19,952$289.25$20,930$2,228.20$978.00JNJ
9$21,642$293.50$24,792$3,191.91$3.1KJNJ
10$23,455$297.54$30,274$4,689.40$6.8KJNJ

VCRA vs JNJ: Complete Analysis 2026

VCRAStock

Vocera Communications, Inc. provides secure, integrated, and intelligent communication and workflow solutions that empowers mobile workers in healthcare, hospitality, retail, energy, education, and other mission-critical mobile work environments in the United States and internationally. The company's communication solution integrates with other clinical systems, including electronic health records, nurse call systems, and patient monitoring, as well as to provide critical data, alerts, alarms, and clinical context that enable workflow. It also offers Vocera Communication and Workflow System, a software platform, which connects communication devices, such as hands-free, wearable, and voice-controlled Smartbadge and badges, as well as third-party mobile devices; and Vocera Care Experience, a hosted software suite that coordinates and streamlines provider-to-patient and provider-to-provider communication and clinical rounding to enhance quality of care, patient and staff experience, reduce care provider's risk, and improve reimbursements, as well as Vocera Ease, a cloud-based communication platform and mobile application to enhance the patient experience by enabling friends and family members to receive timely updates about the progress of their loved one in the hospital. In addition, the company provides professional, software maintenance, and technical support services; and classroom training, distance learning, or customized courseware for systems administrators, IT and industry-specific professionals, and end-user educators. As of December 31, 2020, the company provided its solutions to approximately 1,900 healthcare facilities, including large hospital systems, small and medium-sized local hospitals, clinics, surgery centers, and aged-care facilities. It sells its products through direct sales force, resellers, and distributors. The company was incorporated in 2000 and is headquartered in San Jose, California.

Full VCRA Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this VCRA vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VCRA vs SCHDVCRA vs JEPIVCRA vs OVCRA vs KOVCRA vs MAINVCRA vs ABBVVCRA vs MRKVCRA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.